Your browser doesn't support javascript.
loading
An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus.
McEwan, Phil; Bennett, Hayley; Qin, Lei; Bergenheim, Klas; Gordon, Jason; Evans, Marc.
Afiliação
  • McEwan P; Health Economics and Outcomes Research Ltd, Cardiff, UK.
  • Bennett H; Swansea Centre for Health Economics, Swansea University, Swansea, UK.
  • Qin L; Health Economics and Outcomes Research Ltd, Cardiff, UK.
  • Bergenheim K; Global Health Economics and Payer Analytics, AstraZeneca, Gaithersburg, Maryland.
  • Gordon J; Global Health Economics and Payer Analytics, AstraZeneca, Gothenburg, Sweden.
  • Evans M; Health Economics and Outcomes Research Ltd, Cardiff, UK.
Diabetes Obes Metab ; 19(5): 628-634, 2017 05.
Article em En | MEDLINE | ID: mdl-28026908
AIMS: Time-dependent HbA1c trajectories in health economic models of type 2 diabetes mellitus (T2DM) are typically informed by the UK Prospective Diabetes Study (UKPDS). However, this approach may not accurately predict HbA1c progression in patients who do not conform to the demographic profile of the original UKPDS cohort. This study aimed to develop an alternative mathematical model (MM) to simulate HbA1c progression in T2DM. MATERIALS AND METHODS: A systematic literature review identified studies, published between 2005 and 2015, that reported HbA1c in adult T2DM patients over a minimum duration of 18 months. Pooled data from eligible studies were used to develop an alternative MM equation for HbA1c progression, which was then contrasted with the UKPDS 68 progression equation in illustrative scenarios. RESULTS: A total of 68 studies were eligible for data extraction (mean follow-up time 4.1 years). HbA1c progression was highly heterogeneous across studies, varying with baseline HbA1c, treatment group and patient age. The MM equation was fitted with parameters for mean baseline HbA1c (8.3%), initial change in HbA1c (-0.62%) and upper quartile of maximum observed HbA1c (9.3%). Differences in HbA1c trajectories between the MM and UKPDS approaches altered the timing of therapy escalation in illustrative scenarios. CONCLUSIONS: The MM represents an alternative approach to simulate HbA1c trajectories in T2DM models, as UKPDS data may not adequately reflect the heterogeneity of HbA1c profiles observed in clinical studies. However, the choice of approach should ultimately be determined by the characteristics of individual patients under consideration and the clinical face validity of the modelled trajectories.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemoglobinas Glicadas / Medicina Baseada em Evidências / Diabetes Mellitus Tipo 2 / Economia Médica / Hiperglicemia / Hipoglicemia / Modelos Biológicos Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Systematic_reviews Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemoglobinas Glicadas / Medicina Baseada em Evidências / Diabetes Mellitus Tipo 2 / Economia Médica / Hiperglicemia / Hipoglicemia / Modelos Biológicos Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Systematic_reviews Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article